China SXT Pharmaceuticals, Inc.
SXTC Nasdaq· Pharmaceutical Preparations
Last close · Oct 30, 2026
$3.25
KIRA · Stoqly’s AI analyst, in plain words
- China SXT Pharmaceuticals, Inc. had only $1.1M of revenue in fiscal 2026: it is still developing what it sells.
- Its operating margin was −625.9%, down 471.9 pts: of every 100 in sales, about −626 is left after running the business.
- China SXT Pharmaceuticals, Inc. lost $6.2M in fiscal 2026. With no meaningful sales yet, it pays for its work from the cash it holds.
- Operating cash flow was −$4.0M in fiscal 2026. At that burn of $4.0M a year, its $28.2M of cash and short-term investments would last about 7.0 years.
- China SXT Pharmaceuticals, Inc. has $27.2M more cash than debt.
Market cap
$2.2M
P/E
—
Revenue
$1.1M
Net income
−$6.2M
Free cash flow
—
Operating margin
−625.9%
China SXT Pharmaceuticals, Inc. in 30 seconds · fiscal 2026
Are shareholders being diluted?
+7,053.7%
A lot. The share count rose 7,053.7% last year, so each share owns noticeably less.
Does it make a profit?
—
Not yet. It has no meaningful sales yet, so losses are expected at this stage.
How long would its cash last?
7.0 yrs
Comfortably. It burns $4.0M a year and holds $28.2M, about 7.0 years at that pace.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
4 / 9
It passes 4 of 9 health tests, but most of them need sales, so the score says little before revenue starts.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What China SXT Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 20-F · Jul 1, 2026
- Legal name
- China SXT Pharmaceuticals, Inc.
- CIK
- 0001723980
China SXT Pharmaceuticals, Inc. · SXTC · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.6M | $2.0M | $1.9M | $1.7M | $1.1M |
| Revenue growth | −45.5% | −24.2% | −2.2% | −9.7% | −34.6% |
| Gross margin | 48.1% | 21.6% | 28.7% | 21.1% | 21.9% |
| Operating margin | −199.4% | −284.4% | −130.4% | −154.0% | −625.9% |
| Net income | −$5.7M | −$5.9M | −$3.1M | −$3.3M | −$6.2M |
| Net margin | −220.4% | −301.0% | −160.7% | −189.8% | −545.2% |
| Diluted EPS | −$137.92 | −$177.84 | −$4,285.66 | −$348.17 | −$9.13 |
| Cash | |||||
| Cash from operations | $0.3M | −$0.1M | −$1.9M | −$2.3M | −$4.0M |
| Capital expenditure | — | — | $0.0M | $0.0M | — |
| Free cash flow | — | — | −$1.9M | −$2.3M | — |
| FCF margin | — | — | −100.3% | −134.8% | — |
| Share count change | −94.2% | −19.7% | −97.9% | 1,257.1% | 7,053.7% |
| Debt and strength | |||||
| Cash and short-term investments | $15.5M | $17.4M | $12.1M | $18.1M | $28.2M |
| Debt incl. finance leases | $0.0M | $0.3M | $1.1M | $1.5M | $1.0M |
| Loans, net | $0.0M | $0.0M | — | — | — |
| Deposits | — | — | — | $7.3M | — |
| Shareholders' equity | $16.1M | $14.7M | $13.9M | $15.4M | $29.7M |
| Current ratio | 1.3x | 1.3x | 1.6x | 3.5x | 7.9x |
| Interest coverage | −141.4x | −11.8x | −4.6x | −4.1x | −113.1x |
| Returns and quality | |||||
| Return on capital | −704.9% | — | −66.6% | — | −222.3% |
| Return on equity | −35.8% | −38.6% | −21.7% | −22.5% | −27.5% |
| Return on tangible equity | −35.8% | −40.5% | −22.3% | −21.4% | −20.9% |
| Piotroski F-score | 5 | 3 | 6 | 2 | 4 |
| Altman Z'' | −0.5 | −1.5 | −1.1 | 2.2 | 7.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
China SXT Pharmaceuticals, Inc. · SXTC · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.25 a share, the company is worth $2.2M.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001723980). Latest version: stoqly.net/companies/sxtc. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.